109 related articles for article (PubMed ID: 29707144)
1. Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer.
Dansonka-Mieszkowska A; Szafron LM; Moes-Sosnowska J; Kulinczak M; Balcerak A; Konopka B; Kulesza M; Budzilowska A; Lukasik M; Piekarska U; Rzepecka IK; Parada J; Zub R; Pienkowska-Grela B; Madry R; Siwicki JK; Kupryjanczyk J
Oncotarget; 2018 Apr; 9(25):17735-17755. PubMed ID: 29707144
[TBL] [Abstract][Full Text] [Related]
2. The significance of c.690G>T polymorphism (rs34529039) and expression of the CEBPA gene in ovarian cancer outcome.
Konopka B; Szafron LM; Kwiatkowska E; Podgorska A; Zolocinska A; Pienkowska-Grela B; Dansonka-Mieszkowska A; Balcerak A; Lukasik M; Stachurska A; Timorek A; Spiewankiewicz B; El-Bahrawy M; Kupryjanczyk J
Oncotarget; 2016 Oct; 7(41):67412-67424. PubMed ID: 27602952
[TBL] [Abstract][Full Text] [Related]
3. Expression of EMSY gene in sporadic ovarian cancer.
Altinisik J; Karateke A; Coksuer H; Ulutin T; Buyru N
Mol Biol Rep; 2011 Jan; 38(1):359-63. PubMed ID: 20349280
[TBL] [Abstract][Full Text] [Related]
4. Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas.
van Hattem WA; Carvalho R; Li A; Offerhaus GJ; Goggins M
Int J Clin Exp Pathol; 2008 Jan; 1(4):343-51. PubMed ID: 18787609
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
6. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
7. Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.
Chen P; Huhtinen K; Kaipio K; Mikkonen P; Aittomäki V; Lindell R; Hynninen J; Auranen A; Grénman S; Lehtonen R; Carpén O; Hautaniemi S
Cancer Res; 2015 Aug; 75(15):2987-98. PubMed ID: 26122843
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
9. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
Zhao XD; Zhang Y; He SR; Yang L
Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
[TBL] [Abstract][Full Text] [Related]
10. The function of EMSY in cancer development.
Hou J; Wang Z; Yang L; Guo X; Yang G
Tumour Biol; 2014 Jun; 35(6):5061-6. PubMed ID: 24609898
[TBL] [Abstract][Full Text] [Related]
11. TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens.
Ziółkowska-Seta I; Madry R; Kraszewska E; Szymańska T; Timorek A; Rembiszewska A; Kupryjańczyk J
Gynecol Oncol; 2009 Jan; 112(1):179-84. PubMed ID: 18937971
[TBL] [Abstract][Full Text] [Related]
12. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
13. Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma.
Beussel S; Hasenburg A; Bogatyreva L; Hauschke D; Werner M; Lassmann S
J Clin Pathol; 2012 Jan; 65(1):29-35. PubMed ID: 22011448
[TBL] [Abstract][Full Text] [Related]
14. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data.
Ruckhäberle E; Karn T; Engels K; Turley H; Hanker L; Müller V; Schmidt M; Ahr A; Gaetje R; Holtrich U; Kaufmann M; Rody A
Eur J Cancer; 2010 Feb; 46(3):549-57. PubMed ID: 20022486
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.
Notaro S; Reimer D; Fiegl H; Schmid G; Wiedemair A; Rössler J; Marth C; Zeimet AG
BMC Cancer; 2016 Aug; 16():589. PubMed ID: 27485273
[TBL] [Abstract][Full Text] [Related]
17. Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles.
Murakami R; Matsumura N; Brown JB; Wang Z; Yamaguchi K; Abiko K; Yoshioka Y; Hamanishi J; Baba T; Koshiyama M; Mandai M; Yamada R; Konishi I
Gynecol Oncol; 2016 Apr; 141(1):49-56. PubMed ID: 27016229
[TBL] [Abstract][Full Text] [Related]
18. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
[TBL] [Abstract][Full Text] [Related]
19. Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.
Zhao HY; Huang H; Hu ZH; Huang Y; Lin SX; Tian Y; Lin TY
Anticancer Drugs; 2012 Jun; 23(5):534-42. PubMed ID: 22481060
[TBL] [Abstract][Full Text] [Related]
20. Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer.
Thériault BL; Pajovic S; Bernardini MQ; Shaw PA; Gallie BL
Int J Cancer; 2012 Apr; 130(8):1844-54. PubMed ID: 21618518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
